ReviewCurrent HIV/AIDS reports2011
Preexposure prophylaxis for HIV prevention.
Review in Current HIV/AIDS reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- A Systematic Review and Narrative Synthesis of Factors Affecting Pre-exposure Prophylaxis Willingness Among Black Women for HIV Prevention.AIDS and behavior · 2025Pooled it
- Expanding PrEP Access Through Decentralized Delivery Models.Current HIV/AIDS reports · 2026Review
- Using an Intersectional Framework to Understand the Challenges of Adopting Pre-exposure Prophylaxis (PrEP) Among Young Adult Black Women.Sexuality research & social policy : journal of NSRC : SR & SP · 2022Article
- An Exploration of Pre-exposure Prophylaxis (PrEP) Initiation Among Women Who Inject Drugs.Archives of sexual behavior · 2020Article
- Expanding the Menu of HIV Prevention Options: A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States.AIDS and behavior · 2018Article
- Willingness to Use Pre-Exposure Prophylaxis (PrEP): An Empirical Test of the Information-Motivation-Behavioral Skills (IMB) Model among High-Risk Drug Users in Treatment.AIDS and behavior · 2017Article
- Awareness and Acceptability of Pre-exposure HIV Prophylaxis Among Men Who have Sex with Men in Baltimore.AIDS and behavior · 2017Article
- HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans.Infection · 2016Review
- Knowledge, Attitudes, and Acceptability of Pre-Exposure Prophylaxis among Individuals Living with HIV in an Urban HIV Clinic.PloS one · 2016Article
- Combination HIV prevention interventions: the potential of integrated behavioral and biomedical approaches.Current HIV/AIDS reports · 2014Review
- HIV among men who have sex with men in Malawi: elucidating HIV prevalence and correlates of infection to inform HIV prevention.Journal of the International AIDS Society · 2013Article
- Estimating the efficacy of preexposure prophylaxis for HIV prevention among participants with a threshold level of drug concentration.American journal of epidemiology · 2013Article
- Moving HIV pre-exposure prophylaxis into clinical settings: lessons from buprenorphine.American journal of preventive medicine · 2013Review
- Are Thai MSM willing to take PrEP for HIV prevention? An analysis of attitudes, preferences and acceptance.PloS one · 2013Article
- Access to Basic HIV-Related Services and PrEP Acceptability among Men Who Have sex with Men Worldwide: Barriers, Facilitators, and Implications for Combination Prevention.Journal of sexually transmitted diseases · 2013Article
- Pharmacists as providers of HIV pre-exposure prophylaxis.International journal of clinical pharmacy · 2012Review
- HIV in Africa: Challenges and Directions for the Next Decade.Current infectious disease reports · 2012Article
- The use of preexposure treatments for HIV prophylaxis.HIV/AIDS (Auckland, N.Z.) · 2012Article
- A qualitative study of provider thoughts on implementing pre-exposure prophylaxis (PrEP) in clinical settings to prevent HIV infection.PloS one · 2012Article
- Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a multinational study.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Reducing the incidence of HIV remains one of our greatest public health challenges. However, there is growing optimism that preexposure prophylaxis (PrEP) could have a major impact on preventing incident HIV infection. Recently presented data on the use of oral PrEP in men who have sex with men (MSM) have provided proof-of-principle for this strategy. Additional clinical trials are evaluating whether PrEP provides similar protection to risk groups other than MSM, such as heterosexual persons and injection drug users. Still unanswered questions include optimal dosing strategies, long-term safety, maximizing adherence and minimizing costs, addressing drug resistance in the face of PrEP failure, optimizing access, and assessing effects on risk behavior. Future implementation will be guided by the results of clinical trials in progress. This article provides a review of the data on the potential strengths and limitations of PrEP as an HIV prevention strategy, identifies challenges to implementation of this approach, and outlines knowledge gaps.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.